| Course | HCR 551 Clinical Research Monitoring |
|---|---|
| Module | Module 6 |
| Paper type | Monitoring strategy recommendation paper |
| Length | About 772 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Clinical Research Management |
| Updated | October 2026 |
Free sample paper for HCR 551 Module 6
Monitoring What Matters: A Risk-Based Monitoring Strategy for a 40-Site Phase 3 Trial
Student Name
MS in Clinical Research Management, Arizona State University
HCR 551: Clinical Research Monitoring
Instructor Name
Month Day, Year
Monitoring What Matters: A Risk-Based Monitoring Strategy for a 40-Site Phase 3 Trial
Introduction
For decades, sponsors monitored trials by sending CRAs to every site on a fixed schedule to check every data point against source documents. That model is expensive and, as experience has shown, not especially good at finding the problems that threaten participants or results. Risk-based monitoring (RBM) instead focuses effort on the data and processes most critical to safety and reliability, using central review of accumulating data to decide where and when on-site attention is needed. Good clinical practice now expects this proportionate approach (U.S. Food and Drug Administration, 2025). This paper recommends an RBM strategy for COPD-301, a composite 40-site, 52-week Phase 3 trial of an inhaled therapy in 1,200 adults with chronic obstructive pulmonary disease.
Risk-Based and Central Monitoring
RBM begins with a risk assessment that identifies what could go wrong and how much it would matter. Central monitoring is the engine: data managers and central monitors review accumulating data across sites for outliers, inconsistencies and trends, using statistical methods and key risk indicators. On-site monitoring remains, but it is targeted to sites and activities the central data or the risk assessment flag, and much source review can be done remotely where systems allow.
What the Evidence Shows
Two studies test the approach directly. In ADAMON, 213 sites from 11 academic trials were randomized to extensive on-site monitoring or risk-adapted monitoring; extensive monitoring used about twice as many visits and 2.7 times as much on-site time, yet independent audits found risk-adapted monitoring non-inferior in the proportion of patients with major findings (Brosteanu et al., 2017). TEMPER compared sites visited because central triggers fired with matched sites that had not triggered a visit. Triggered visits found new major or critical findings at 88.1% of sites against 81.0% of untriggered sites, a difference that was not significant, although the gap widened when consent re-signature findings were excluded (Stenning et al., 2018). Together, the studies suggest that less on-site monitoring is not worse and that triggers need careful design to discriminate well.
Recommended Strategy for COPD-301
Risk Assessment
The critical data and processes are spirometry for the primary endpoint, exacerbation reporting for a key secondary endpoint, inhaler technique and adherence, eligibility based on spirometry and smoking history and serious adverse event reporting.
Key Risk Indicators
| Indicator | Why it matters | Threshold for action |
|---|---|---|
| Spirometry sessions failing quality criteria | Primary endpoint reliability | More than 10% of a site's sessions in a quarter |
| Exacerbation rate far from trial mean | Under- or over-reporting of a key endpoint | Site rate outside the trial's 5th to 95th percentile |
| Dose counter adherence below 80% | Treatment exposure | More than 15% of a site's participants |
| Screen failure rate | Possible eligibility misunderstanding | Twice the trial median |
| Days from adverse event onset to entry | Safety reporting timeliness | Median above 7 days |
| Data entry lag | Ability to monitor centrally | Median above 5 days after visit |
Monitoring Mix
Central monitoring reviews these indicators weekly, with statistical checks across sites every month. Remote source review covers consent, eligibility and serious adverse events for every participant. On-site visits occur at site initiation, after the first three participants and then only when indicators breach thresholds or remote review finds issues. Every site receives at least one on-site visit a year.
CRA Oversight and Decisions
CRAs become site relationship managers and investigators of signals: when an indicator breaches, the CRA reviews the data, contacts the site, decides between remote follow-up and an on-site visit and documents the decision and outcome. Escalation goes to the study manager when the same indicator breaches twice.
Risk Mitigation Strategies
| Risk | Mitigation |
|---|---|
| Poor spirometry quality | Central over-read of every session, site feedback within 48 hours, coaching for technicians |
| Missed exacerbations | Weekly diary questions, call to participants missing diary entries, standard definitions training |
| Low adherence | Dose counter review at each visit; retraining in inhaler technique |
| Eligibility errors | Central spirometry confirmation before randomization |
| Late safety reporting | Automated alerts for unreported serious events in the diary; CRA follow-up within 24 hours |
Limitations
RBM depends on timely data entry; if sites enter data late, central monitoring sees problems late. Thresholds will need tuning after the first quarter, since TEMPER showed that triggers can fail to separate high- and low-risk sites. Some findings, especially around consent documents, still require someone to look at source.
Conclusion
A risk-based strategy for COPD-301 concentrates effort on spirometry, exacerbations, adherence, eligibility and safety reporting, uses central monitoring to decide where to look and keeps on-site visits for when they add value. The evidence supports doing less routine on-site work, provided central indicators are well designed and CRAs act on them.
References
Brosteanu, O., Schwarz, G., Houben, P., Paulus, U., Strenge-Hesse, A., Zettelmeyer, U., Schneider, A., & Hasenclever, D. (2017). Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study. Clinical Trials, 14(6), 584-596. https://doi.org/10.1177/1740774517724165
Stenning, S. P., Cragg, W. J., Joffe, N., Diaz-Montana, C., Choudhury, R., Sydes, M. R., & Meredith, S. (2018). Triggered or routine site monitoring visits for randomised controlled trials: Results of TEMPER, a prospective, matched-pair study. Clinical Trials, 15(6), 600-609. https://doi.org/10.1177/1740774518793379
U.S. Food and Drug Administration. (2025). E6(R3) good clinical practice (GCP) [Guidance for industry]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
HCR 551 Module 6 instructions, in plain terms
The Central Monitoring and Analytics Paper is the major written deliverable in HCR 551, built in stages: Draft 1 covers the introduction, an overview of risk-based monitoring and its benefits, Draft 2 adds risk mitigation strategies and a conclusion, and the final submission, worth 100 points in Week 6, is the revised and edited paper. The syllabus asks you to analyze and recommend a monitoring strategy using concepts of CRA oversight, central monitoring tools, risk indicators and operational decision-making. A recommendation needs something to recommend for, so ground the paper in one trial, real or realistic, and make the strategy specific: what the critical data are, which indicators will be watched, what thresholds trigger action and how CRAs will respond. Evidence from studies that compared monitoring approaches will strengthen the case more than general claims about efficiency.
Inside the HCR 551 Module 6 example
The paper opens with the shift from routine on-site monitoring to risk-based approaches and names the trial it will plan for. It explains RBM and central monitoring briefly, then reports two comparative studies with their numbers, including one with a disappointing result. The recommendation section has four parts: the risk assessment, a table of key risk indicators with reasons and thresholds, the monitoring mix and the CRA's decision role. A second table pairs five risks with mitigation strategies, a limitations section notes what the strategy cannot do and the conclusion restates the recommendation in two sentences. Indicator thresholds are stated as numbers, so a reader can see exactly when a CRA would act.
Where the marks sit in the HCR 551 Module 6 rubric
The final RBM paper is worth 100 points, with earlier drafts graded separately. A strong paper explains risk-based and central monitoring accurately, uses evidence to support the approach, makes a specific recommendation for a defined trial, defines measurable key risk indicators with thresholds, describes the CRA's oversight and decisions and includes mitigation strategies and limitations, incorporating feedback from the drafts. Points are lost when the paper describes RBM in general without a recommendation, when indicators lack thresholds, when evidence is absent or overstated and when draft feedback is ignored. Readers value papers that admit what central monitoring cannot catch, since a credible recommendation shows its own limits. Feedback from earlier drafts should be visible in the final version.
HCR 551 Module 6 help from the desk
Pick a trial and list its critical data before writing. Use at least two studies that compare monitoring approaches. Put indicators, reasons and thresholds in a table. Say exactly what a CRA does when a threshold is breached. Add mitigation strategies tied to specific risks. Include limitations. Carry draft feedback forward and keep a list of changes. If you want help setting realistic thresholds, the desk can review your indicator table. State the trial's critical data in the first paragraph of your strategy so every later choice can be traced to them. Keep the CRA's decision rules short enough to fit on one page of a monitoring plan. Avoid recommending central monitoring without saying who reviews the data and how often.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 551 and MS in Clinical Research Management sample papers
- HCR 551 Module 3: CAPA Writing Assignment
- HCR 593 Module 5: Introduction and Background (Review of the Literature)
- HCR 574 Module 2: Paper 2: Common Rule Application, Narrated Slides
- HCR 561 Module 3: Assignment 1: Slides for Site Staff on an Ethical Issue
- HCR 566 Module 2: Capstone Proposal
HCR 551 Module 6 questions, answered
Where can I find a free HCR 551 Module 6 sample paper?
Above on this page is the full final RBM paper recommending a monitoring strategy for a 40-site COPD trial.
What is risk-based monitoring?
Monitoring that focuses on the data and processes most critical to safety and reliability, using central review to decide where on-site effort is needed.
Is risk-adapted monitoring as good as full on-site monitoring?
In the ADAMON study, it was non-inferior in major audit findings while using far fewer visits.
What are key risk indicators?
Measures such as data entry lag or adverse event reporting time, watched across sites with thresholds that trigger action.
How is the HCR 551 RBM paper built?
Through drafts covering the introduction and overview, then mitigation strategies and conclusion, before a final 100-point submission.